12 September 2018
A new report by visiongain forecasts the world gene therapy industry will achieve revenues of $204m in 2020, with potential to multiply further in sales to 2026. Those revenues will expand from 2016 to 2026 as new genetic treatments reach the market and develop that industry. That prediction and others appear in Gene Therapy R&D and Revenue Forecasts 2016-2026: Prospects for Drugs Treating Cancer, Cardiovascular Disorders, Eye Conditions, Rare Diseases and Other Needs.
Visiongain, a business information publisher and consultancy in London, UK, releases that study in January 2016. That survey analyses events, prospects and opportunities shaping the development, production and sale of genetic treatments. The new analysis shows multilevel revenue forecasting, qualitative analyses and interviews. It also assesses leading companies – their products, strategies and R&D. Visiongain’s purpose is to help organisations explore the potentials of industries and markets.
Gene therapy involves the administration of a gene to treat a disease. Those treatments aim to be delivered only once or a few times rather than as a medicine administered long-term. Gene therapies could potentially cure a disease using methods such as adding a gene, correcting it, or using genetic material to cause cell death. That emerging market has attracted interest from pharma companies big and small, a trend likely to continue. Visiongain predicts expansion in gene therapy revenues from 2016 to 2026, building upon the extensive research and development in that biotechnological field. That medicine holds great promise for pharma companies and patients, the new study explains.
In 2015, the cancer treatment submarket formed the most lucrative part of that industry. However that segment will shift in market share from 2016 to 2026 and lose a large percentage of its market share to the rare disease treatment submarket and the cardiovascular disease submarket. That trend will result from the rare disease pipeline and cardiovascular disorder pipeline launching their treatments first as their pipeline candidates are later in development. Gene therapies in development will bring in a new era for disease treatment and make a difference in long-term benefits for patients.
Mashael Zaidi, a pharmaceutical industry analyst in visiongain, said: “The gene therapy market is currently at a pivotal point in its development, with new treatments set to reach a market that has yet to establish itself. A lot of the success of this market will depend on the decisions made now on issues such as pricing, reimbursement and regulations. Gene therapy must gain acceptance from cautious regulators, potential users and payers by not only proving its efficacy and safety, but dealing with issues of cost. In the past ethics has been a controversial topic for gene therapy and will continue to affect its potential.”
In this report visiongain defines gene therapy products as those that modify the expression of particular genes or that correct abnormal genes. Therefore this study excludes a number of products that may be considered as gene therapies, but only under wider definitions, such as gene silencing and oligonucleotide therapies, antisense therapy and treatments that boost the immune response.
Visiongain’s new investigation shows revenue predictions to 2026 for gene therapy at overall world market, submarket and product level. First it forecasts the following five therapeutic applications at world level to 2026:
• Cancer (oncology)
• Cardiovascular diseases
• Ophthalmological disorders
• Rare medical conditions, including inherited and hard-to-treat disorders
• Other applications of that biotechnology in human healthcare.
That study next forecasts revenues of two marketed products to 2026:
The report also discusses these brands: Gendicine and Oncorine. In addition the investigation gives 12 discussions for leading compounds in development, including revenue forecasting to 2026 for these six drug candidates:
• GSK2696273 (GSK)
• Collategene/AMG0001 (AnGes MG/Vical)
• BC-819 (BioCancell)
• Lenti-D (Bluebird Bio)
• SPK-RPE65 (Spark Therapeutics)
• Invossa/TissueGene-C (TissueGene/Kolon Life Science).
That work examines leading countries, assessing regulations and other forces affecting gene therapy, especially in the United States, the European Union and Japan. The study also shows interviews with Lysogene, Cell Therapy Catapult and the Human Stem Cells Institute.
Visiongain’s new survey also explores leading companies. That investigation discusses acquisitions, other deals, collaborations and R&D. Organisations discussed include these:
• Bristol-Myers Squibb
• Bayer Healthcare
• Bluebird Bio
• Spark Therapeutics.
Gene Therapy and Revenue Forecasts 2016-2026: Prospects for Drugs Treating Cancer, Cardiovascular Disorders, Eye Conditions, Rare Diseases and Other Needs adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, biotechnology, medical devices, diagnostics and outsourced services.
Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.
19 April 2021
The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.
12 April 2021
Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.
09 April 2021
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.